Physician profile
Jennifer Fleming
NPI 1376097071
$1,294.60
in general payments reported to CMS, 2019-2025
18 companies · $516 in 2025
The $516 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.38 · 2024: $733 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $169.12 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $149.18 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $147.46 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $139.71 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $113.00 | 2024 | Rezdiffra |
| Genzyme Corporation | $103.24 | 2025 | |
| Janssen Scientific Affairs, LLC | $100.51 | 2024 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $72.47 | 2024-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $48.05 | 2024-2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $46.87 | 2024 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $39.42 | 2025 | Dupixent |
| Celgene Corporation | $36.56 | 2024 | Zeposia |
| Organon LLC | $28.24 | 2022 | |
| Mirum Pharmaceuticals, INC. | $22.98 | 2025 | Livmarli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.41 | 2025 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.85 | 2024 | |
| Astellas Pharma US INC | $19.39 | 2024 | Xospata |
| Coopersurgical, INC. | $17.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.